Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tuberculosis in India: Challenges, Initiatives, and Recommendations

Tuberculosis in India: Challenges, Initiatives, and Recommendations 1171498 APHXXX10.1177/10105395231171498Asia Pacific Journal of Public HealthKochhar et al research-article2023 Short Communication Asia Pacific Journal of Public Health 1 –3 Tuberculosis in India: Challenges, © 2023 APJPH Article reuse guidelines: sagepub.com/journals-permissions Initiatives, and Recommendations https://doi.org/10.1177/10105395231171498 DOI: 10.1177/10105395231171498 journals.sagepub.com/home/aph 1 2 Gunjan Kochhar, MBBS , Omer Ahmed Shaikh, MBBS , 2 2 Rameel Muhammad Aftab, MBBS , Manisha Essarani, MBBS , 3 4 Sidhant Ochani, MBBS , and Kaleem Ullah, FCPS Mycobacterium tuberculosis is a respiratory pathogen that turn, noncompliance increases the risk of drug resistance to primarily affects the lungs. The incidence (new cases per first-line agents such as isoniazid and rifampicin. Unregulated year per million population) of tuberculosis (TB) in India for private prescription of these drugs has led to a rise in resis- 2021 is 210 cases per 1 00 000 population. India accounts for tant forms. More extensive testing for rifampicin resistance 28% of the total new cases worldwide. The highest number is required in today’s world to prevent suboptimal treatment of cases are reported from the Delhi region, that is, 747 cases and further evolution of resistant cases. Adverse drug reac- per 1 00 000 population, followed by Haryana (477) and tions of first-line agents http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia Pacific Journal of Public Health SAGE

Loading next page...
 
/lp/sage/tuberculosis-in-india-challenges-initiatives-and-recommendations-zShTHuOrwD

References (10)

Publisher
SAGE
Copyright
© 2023 APJPH
ISSN
1010-5395
eISSN
1941-2479
DOI
10.1177/10105395231171498
Publisher site
See Article on Publisher Site

Abstract

1171498 APHXXX10.1177/10105395231171498Asia Pacific Journal of Public HealthKochhar et al research-article2023 Short Communication Asia Pacific Journal of Public Health 1 –3 Tuberculosis in India: Challenges, © 2023 APJPH Article reuse guidelines: sagepub.com/journals-permissions Initiatives, and Recommendations https://doi.org/10.1177/10105395231171498 DOI: 10.1177/10105395231171498 journals.sagepub.com/home/aph 1 2 Gunjan Kochhar, MBBS , Omer Ahmed Shaikh, MBBS , 2 2 Rameel Muhammad Aftab, MBBS , Manisha Essarani, MBBS , 3 4 Sidhant Ochani, MBBS , and Kaleem Ullah, FCPS Mycobacterium tuberculosis is a respiratory pathogen that turn, noncompliance increases the risk of drug resistance to primarily affects the lungs. The incidence (new cases per first-line agents such as isoniazid and rifampicin. Unregulated year per million population) of tuberculosis (TB) in India for private prescription of these drugs has led to a rise in resis- 2021 is 210 cases per 1 00 000 population. India accounts for tant forms. More extensive testing for rifampicin resistance 28% of the total new cases worldwide. The highest number is required in today’s world to prevent suboptimal treatment of cases are reported from the Delhi region, that is, 747 cases and further evolution of resistant cases. Adverse drug reac- per 1 00 000 population, followed by Haryana (477) and tions of first-line agents

Journal

Asia Pacific Journal of Public HealthSAGE

Published: May 1, 2023

There are no references for this article.